Clinical Trials Logo

Clinical Trial Summary

The study will include 30 elderly patients age 60-85 with primary CNS DLBCL . Induction treatment will include Rituximab and high dose methotrexate protocol (containing at least methotrexate and one more chemotherapy agent). Patients with MRI documented response CR or PR will enter the study protocol maintenance phase which will include continous treatment with Ibrutinib 560 mg day until relapse or disease progression or occurrence of limiting toxicities


Clinical Trial Description

30 elderly patients age 60-85 with primary CNS DLBCL who will achieve response CR or PR will enter the study protocol maintenance phase. Induction treatment will include Rituximab and high dose methotrexate protocol (containing at least methotrexate and one more chemotherapy agent). Patients with MRI documented response CR or PR will enter the study protocol maintenance phase. Maintenance: 28 day cycles of Ibrutinib 560 mg orally once daily until relapse or disease progression or occurrence of limiting toxicities Evaluation of response: Radiologic evaluation by MRI will be performed every 3 months. Neurologic status evaluation every 2 months Neurocognitive evaluation every 6 months ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02623010
Study type Interventional
Source Rabin Medical Center
Contact Osnat Bairey, MD
Phone 972504065471
Email osnatb@clalit.org.il
Status Recruiting
Phase Phase 2
Start date October 2016
Completion date December 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04516655 - A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients Phase 2
Recruiting NCT05054426 - Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL Phase 3
Recruiting NCT04548648 - A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas Phase 2
Active, not recruiting NCT00293475 - Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Phase 1/Phase 2
Completed NCT03342586 - Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity
Terminated NCT02420795 - Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Phase 1/Phase 2
Completed NCT01011920 - Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma Phase 2
Completed NCT00967200 - Study of Tissue Samples From Patients With Glioma or Other Brain Tumors N/A
Recruiting NCT03684980 - LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma Early Phase 1
Not yet recruiting NCT06213636 - Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). Phase 1/Phase 2
Recruiting NCT04938297 - Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma Phase 2
Recruiting NCT04792489 - DALY II USA/ MB-CART2019.1 for DLBCL Phase 2
Completed NCT01458730 - Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma Phase 2
Completed NCT00153530 - Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Phase 4
Recruiting NCT04186520 - CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies Phase 1/Phase 2
Recruiting NCT05816746 - Decitabine and Anti-PD-1 in R/R DLBCL Phase 2
Recruiting NCT06031194 - Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
Active, not recruiting NCT03962127 - MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway
Completed NCT03690895 - Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy
Recruiting NCT05114330 - Secondary Central Nervous System Lymphoma Registry - Charité